Mineralys Q3 net loss widens to $56.3M; pivotal trial enrollments complete, data due H1 2025

Mineralys Therapeutics, Inc.

2024-Q3 EPS reported -$2.68

Net loss of $56.3M for Q3 2024 vs $22.8M in Q3 2023; R&D expense rose to $54.0M from $22.5M.
Cash & investments $263.6M; company believes sufficient to fund operations into 2026.
Advance-HTN pivotal trial fully enrolled; topline data expected March 2025.
Launch-HTN Phase 3 trial enrolled ahead of schedule; topline data anticipated mid first half 2025.
Explore-CKD Phase 2 trial enrollment ongoing; topline data expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.